Reversibility of cirrhosis in autoimmune hepatitis

American Journal of Medicine

Volumn 117, Issue 2, 2004, Pages 125-129

  Malekzadeh, Reza ^a,d   Mohamadnejad, Mehdi ^c   Nasseri Moghaddam, Siavosh ^a   Rakhshani, Nasser ^a   Tavangar, Seyed Mohamad ^b   Sohrabpour, Amir Ali ^a   Tahaghoghi, Soosan ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; ASPIRATION CYTOLOGY; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TISSUE FIXATION; TISSUE SECTION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLOBULINS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 3242734673     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.01.026     Document Type: Article

References (16)

1. Crawford J.M. The liver and the biliary tract. Cotran R.S., Robbins S.L., Kumar V., Schoen F.J. Pathologic Basis of Disease. 5th ed :1994;831-896 W.B. Saunders, Philadelphia, Pennsylvania
2. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 344:2001;418-423
3. Dufour J.F., DeLellis R., Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 127:1997;981-985
4. Poynard T., McHutchison J., Davis G.L., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 32:2000;1131-1137
5. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepato. 22:1995;696-699
6. Friedman S.L. The cellular basis of hepatic fibrosis mechanisms and treatment strategies. N Engl J Med. 328:1993;1828-1835
7. Bonis P.A., Friedman S.L., Kaplan M.M. Is liver fibrosis reversible? N Engl J Med. 344:2001;452-454
8. Sobesky R., Mathurin P., Charlotte F., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C a dynamic view. The Multivirc Group. Gastroenterology. 116:1999;378-386
9. Cotler S.J., Jakate S., Jensen D.M. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol. 32:2001;428-430
10. Malekzadeh R., Mohamadnejad M., Nasseri-Moghaddam S., et al. mpact of treatment of liver fibrosis in autoimmune hepatitis and chronic hepatitis B. Gastroenterology. 124:(4 suppl 1):2003;A382
11. Malekzadeh R., Nasseri-Moghaddam S., Kaviani M.J., et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 46:2001;1321-1327
12. Vergani D., Choudhuri K., Bogdanos D.P., et al. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 6:2002;439-449
13. Kim W.U., Cho M.L., Kim S.I., et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol. 27:2000;324
14. Marzano A., Trapani A., Leone N., et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin A. Ann Rheum Dis. 60:2001;427-428
15. Filaci G., Cutolo M., Scudeletti M., et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxf). 38:1999;992-996
16. Filaci G., Cutolo M., Basso M., et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxf). 40:2001;1431-1432